Femasys Inc. FEMY

Company Overview

Femasys Inc. is a U.S.-based biomedical company focused on women’s health, with a primary emphasis on infertility, reproductive medicine, and minimally invasive gynecologic solutions. The company develops and commercializes diagnostic and therapeutic products intended for office-based use by healthcare providers. Femasys operates within the medical device and women’s healthcare industries, targeting unmet needs in fertility treatment and reproductive health management. Its core revenue drivers include infertility diagnostics, fallopian tube assessment technologies, and emerging reproductive intervention products designed to reduce reliance on more invasive or costly procedures.

The company’s principal commercial products include FemaSeed, an intratubal insemination product for infertility treatment, and FemVue, a saline-air contrast sonography system used to evaluate fallopian tube patency. Femasys also develops investigational and pipeline products such as FemBloc, a non-surgical permanent birth control candidate, and other reproductive health technologies. Founded in 2004 and headquartered in Georgia, the company evolved from a development-stage medical technology enterprise into a publicly traded commercial-stage company listed on Nasdaq under the ticker FEMY. Its strategic positioning centers on offering office-based alternatives to surgical or resource-intensive fertility and gynecologic procedures.